James Larzalere, MD
Adolescent Medicine · McPherson, KSNPI 1184690695
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 80 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 19 manufacturers, the largest accounting for just 22.1% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $381 and has fallen 72.3% since, to $106 in 2024.
Across 80 payments — averaging $15.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$277
- Lilly USA, LLC$139
- Eisai Inc.$105
- Novo Nordisk$96
- Boehringer Ingelheim$86
- Amgen$79
- plus $473 from 13 others
What the payments were for
- Food & beverage$1,256100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 17 | $277 |
| Lilly USA, LLC | 9 | $139 |
| Eisai Inc. | 6 | $105 |
| Novo Nordisk | 6 | $96 |
| Boehringer Ingelheim | 6 | $86 |
| Amgen | 5 | $79 |
| AbbVie | 4 | $69 |
| Novartis | 4 | $50 |
| Merck | 4 | $50 |
| Dexcom, Inc. | 2 | $48 |
| Adamas Pharmaceuticals, Inc. | 3 | $47 |
| Sanofi-aventis U.S. LLC | 3 | $42 |
| Pfizer | 2 | $35 |
| Astellas Pharma US Inc | 2 | $32 |
| Xeris Pharmaceuticals, Inc. | 2 | $31 |
| E.r. Squibb & Sons, L.L.C. | 2 | $28 |
| Mylan Specialty L.p. | 1 | $16 |
| Johnson & Johnson | 1 | $14 |
| Genentech USA, Inc. | 1 | $11 |
How this compares
Too few adolescent medicine providers in Kansasto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 132 | $68,259 |
| MounjaroTirzepatide | 28 | $27,568 |
| MyrbetriqMirabegron | 23 | $19,647 |
| JardianceEmpagliflozin | 26 | $17,885 |
| LinzessLinaclotide | 20 | $11,473 |
| GemtesaVibegron | 22 | $11,378 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 20 | $8,492 |
| Breo ElliptaFluticasone/Vilanterol | 18 | $7,595 |
| XareltoRivaroxaban | 15 | $7,056 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 14 | $4,441 |
| Potassium Chloride | 199 | $4,375 |
| Aspirin-Dipyridamole ErAspirin/Dipyridamole | 12 | $3,349 |
| Celecoxib | 32 | $2,887 |
| Levothyroxine Sodium | 335 | $2,774 |
| Insulin Lispro Kwikpen U-100Insulin Lispro | 18 | $2,444 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $35 | $68,259132 claims |
| Lilly USA, LLCMounjaro | $139 | $27,56828 claims |
| Astellas Pharma US IncMyrbetriq | $32 | $19,64723 claims |
| Boehringer IngelheimJardiance | $86 | $17,88526 claims |
| AbbVieLinzess | $69 | $11,47320 claims |
| Johnson & JohnsonXarelto | $14 | $7,05615 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few adolescent medicine providers in Kansason file to place this against a meaningful peer group, so we don't.
Other adolescent medicine in McPherson
- Jennifer MellickOverland Park$2K
- Kristen StuppyOverland Park$1K
- Amy VoelkerOlathe$1K
- Greg BibersteinManhattan$1K
- Steven HaugManhattan$970
- Rebecca KlinglerManhattan$967
- Stuart ShankerOlathe$763
- Robert DuffManhattan$570
- Camille HeebTopeka$264
- Robert CooleyKansas City$124
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.